Tag: rituximab
Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression
Neel Mistry -
1. Among patients categorized as B-cell poor group via RNA sequencing, tocilizumab had a significantly higher response rate than rituximab.
2. Likelihood of adverse events and serious adverse events were comparable between both treatment groups.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Rheumatoid arthritis is a chronic autoimmune condition with considerable morbidity...
1. Rituximab was found to significantly reduce median time to remission in new-onset myasthenia gravis.
2. Rituximab appeared to outperform conventional immunosuppressant therapy in terms of need for rescue therapy and adverse effects resulting in discontinuation.
Evidence Rating Level: 2 (Good)
Myasthenia gravis (MG) is a serious neuromuscular disease, resulting from an autoreactive humoral...
1. In this randomized controlled trial involving patients with antineutrophil cytoplasmic antibody-associated vasculitis in complete remission, administration of rituximab for an additional 18 months was associated with a lower likelihood of relapse versus placebo.
2. Although the vast majority of patients in both groups reported at least 1 adverse event,...
Association of Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing Positive for Coronavirus Disease 2019 (COVID-19)
1. No association was found between angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use and test-positivity for COVID-19.
Evidence Rating Level: 2 (Good)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the...
#VisualAbstract: Eculizumab in Aquaporin-4–Positive Neuromyelitis Optica Spectrum Disorder
Constance Wu -
1. In this randomized control trial of neuromyelitis optica spectrum disorder (NMOSD) patients with aquaporin-4 antibodies (AQP4-IgG), those randomized to receive the eculizumab complement inhibitor experienced a lower relapse rate over 24 months than placebo treated patients.
2. Eculizumab patients more commonly experienced upper respiratory tract infections (URI) and headaches.
Evidence...
#VisualAbstract: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Constance Wu -
1. Previously untreated chronic lymphocytic leukemia (CLL) patients experienced increased progression-free and overall survival when treated with ibrutinib-rituximab compared to current standard chemoimmunotherapy.
2. Rates of high grade adverse events were similar between treatment groups.
Evidence Rating Level: 1 (Excellent)
Study Rundown: CLL is a common hematologic malignancy often treated with a...